Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2GZM3
|
|||
| Drug Name |
EG12014
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 3 | [1] | |
| Company |
EirGenix Taipei, Taiwan Sandoz Princeton, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03433313) A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.